Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac<sup>®</sup> and ChAdOx1-S Vaccines for SARS-CoV-2
Coronavirus disease 2019 (COVID-19) has been extensively researched, particularly with regard to COVID-19 vaccines. However, issues with logistics and availability might cause delays in vaccination programs. Thus, the efficacy and safety of half-dose heterologous mRNA should be explored. This was an...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2024-03-01
|
| Saila: | Vaccines |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/2076-393X/12/4/344 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
